People who can't afford the name-brand drugs have been flocking to compounded versions, which are available at a fraction of ...

Hims & Hers (HIMS), the millennial-skewed telehealth company, saw its stock tumble nearly 9% on Tuesday, as the company ...

The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.

Telehealth company Hims & Hers Health (HIMS) witnessed a major dip in its stock recently despite reporting 95% revenue growth ...

What Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 8% in the afternoon session after the U.S.

Hims & Hers Health ( HIMS -7.38%) stock slid 7.4% through 11:10 a.m. ET Tuesday after Bank of America raised its price target ...

Hims & Hers Health ( HIMS 3.08%) stock jumped 2.2% through 10:45 a.m. ET Monday after Morgan Stanley analyst Craig Hettenbach ...

With the FDA shutting down its key revenue stream, Hims faces a tough road ahead--can it justify its valuation?

After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...

Telehealth company Hims & Hers (HIMS) saw a major boost in app downloads during February. According to a Top-rated analyst, Craig ...

Hims & Hers Health (NYSE: HIMS) has been a top healthcare stock to own over the past five years, soaring by around 350% ...